News - Bayer, Licensing

Filter

Current filters:

BayerLicensing

Popular Filters

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201

02-06-2014

Finland-based drugmaker Orion Corp has entered into a global partnership with German pharma major Bayer…

BayerGlobalLicensingODM-201OncologyOrion CorpPharmaceuticalResearch

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer

11-03-2014

US biotech firm KYTHERA Biopharmaceuticals says it has re-acquired all rights outside of the USA and…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsLicensingNorth AmericaPharmaceutical

X-Chem licenses drug discovery program to Bayer

X-Chem licenses drug discovery program to Bayer

17-02-2014

X-Chem Inc, a privately held US biotechnology company focused on applying its innovative drug discovery…

BayerBiotechnologyLicensingOncologyX-Chem

Regeneron and Bayer expand deal to develop new option for wet-AMD

Regeneron and Bayer expand deal to develop new option for wet-AMD

14-01-2014

US biotech firm Regeneron Pharmaceuticals said yesterday that it has expanded its accord with German…

BayerBiotechnologyEyleaLicensingOphthalmicsRegeneronResearch

Bayer enters a further academic collaboration on innovative cancer therapies

10-09-2013

In a further collaboration with academia, German pharma and chemical major Bayer (BAYN: DE) has entered…

BayerLicensingOncologyPharmaceuticalResearch

Bayer inks multi-million dollar cancer immunotherapy deal

05-08-2013

Germany's largest pharma company Bayer (BAYN: DE) has entered into a new oncology collaboration and license…

BayerCompugenLicensingOncologyPharmaceuticalResearch

Paladin Labs acquires Binotal rights in Latin America from Bayer

03-07-2013

Canadian specialty pharma firm Paladin Labs (TSX: PLB) has signed an agreement with German drug major…

Antibiotics and Infectious diseasesBayerBinotalLicensingPaladin LabsPharmaceuticalSouth America

Bayer to spend up to $520 million on antibody drug conjugate deal with Seattle Genetics

26-06-2013

US biotech firm Seattle Genetics (Nasdaq: SGEN) says it has entered into a new antibody-drug conjugate…

BayerBiotechnologyLicensingOncologyPharmaceuticalSeattle Genetics

News briefs from Bayer, AstraZeneca and Valeant/Galderma

06-12-2012

German drug major Bayer (BAYN: DE) and partner Regeneron (Nasdaq: REGN) submitted a marketing application…

AstraZenecaBayerEuropeEyleaFaslodexGaldermaLicensingNorth AmericaOncologyOphthalmicsPerlanePharmaceuticalRegulationRestylaneValeant Pharmaceuticals

Bayer inks up to 592 million-euro endometriosis deal with Evotec

02-10-2012

Drug major Bayer (BAYN: DE) and fellow German company Evotec (EVT: TecDAX) have entered into a five-year,…

BayerEvotecLicensingPharmaceuticalWomen's Health

Nordic Group gets ex-US right to Trasylol from Bayer

15-07-2012

Privately-held Netherlands-based Nordic Group has reached an agreement with Germany's Bayer (BAYN: DE)…

BayerCardio-vascularLicensingNordic GroupPharmaceuticalTrasylol

KYTHERA Biopharma gets $33.3 million in payments from Bayer

07-06-2012

Privately-held US biotech firm KYTHERA Biopharmaceuticals says it has received a $15.8 million payment…

BayerBiotechnologyFinancialKYTHERA BiopharmaceuticalsLicensingPharmaceuticalResearch

Roche returns rights to TB-403 to ThromboGenics and BioInvent, who abandon TB-402 development

05-06-2012

Belgium-based biopharma company ThromboGenics NV (Euronext Brussels: THR) and co-development partner…

BayerBioInventBiotechnologyLicensingOncologyOphthalmicsPharmaceuticalRocheTB-402TB-403ThromboGenicsXarelto

Milestone payment for Ardea from Bayer, which executes license with Dyax

31-05-2012

AstraZeneca (The Pharma Letter April 23), said yesterday that it has earned a $7.5 million milestone…

Ardea BiosciencesBAY 86-9766BayerDyax CorpFinancialLicensingOncologyPharmaceuticalResearch

Santen to co-promote Bayer and Regeneron's Eylea in Japan

09-05-2012

German drug major Bayer's (BAYN: DE) Japanese subsidiary, Bayer Yakuhin, and Santen Pharmaceutical (TYO:…

Asia-PacificBayerEyleaLicensingMarkets & MarketingOphthalmicsPharmaceuticalRegeneronSanten Pharmaceuticals

Algeta takes up option to co-promote Alpharadin in the USA

13-04-2012

Norwegian cancer therapeutics developer Algeta ASA (OSE: ALGETA) says that it has exercised its option…

AlgetaAlpharadinBayerLicensingMarkets & MarketingOncologyPharmaceutical

Bayer settles with Onyx over Nexavar and regorafenib with $160 million payment

13-10-2011

US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) and German pharma major Bayer HealthCare, a unit of…

BayerLegalLicensingNexavarOncologyOnyx PharmaceuticalsPharmaceuticalregorafenib

Back to top